A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules Given Daily for 21 Days Followed by 7 Days Off Schedule in Patients With Advanced Solid Tumors

Trial Profile

A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules Given Daily for 21 Days Followed by 7 Days Off Schedule in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2017

At a glance

  • Drugs Minnelide (Primary) ; Paclitaxel
  • Indications Breast cancer; Colorectal cancer; Gastric cancer; Pancreatic cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Minneamrita Therapeutics
  • Most Recent Events

    • 24 Oct 2017 According to a Minneamrita Therapeutics media release, HonorHealth Research Institute is the first clinical site to be open for enrollment for this clinical trial. Additional sites are planned to be opened and enrolling patients in the coming months, including the Mayo Clinic.
    • 24 Oct 2017 According to a Minneamrita Therapeutics media release, an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for this trial is now active. The first patient to participate in this exciting clinical trial received treatment this past week at HonorHealth Research Institute.
    • 19 Oct 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top